A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis. Ge A, Sun Y, Kiker T, Zhou Y, et al. J Neuroimmunol 2023;379:578105.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ge A, Sun Y, Kiker T, Zhou Y, et al. A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis. J Neuroimmunol 2023;379:578105.
PMID: 37207441